Disc Medicine, Inc.

Disc Medicine, Inc., trading under ticker GMTX, is a clinical-stage biopharmaceutical company that entered the public markets through its merger with Panacea Acquisition Corp., a healthcare-focused special purpose acquisition company. The SPAC completed its business combination in early 2021, bringing the company — then operating as Gemini Therapeutics — into the public sphere with a focus on complement-mediated diseases before subsequently pivoting its strategic direction toward hematology and rebranding as Disc Medicine. The December 2022 Form 8-K filing, accession number 0001140361-22-047153, reflects continued disclosure obligations as the post-merger entity navigated its operational and corporate evolution. The company operates in the biopharmaceutical sector. Sign up for full data, filings, and deal history on SpacDesk.